Prozac, antifungal drug inhibit SARS-CoV-2 in new study
Two common antidepressant and antifungal drugs were very effective at inhibiting SARS-CoV-2, the virus that causes COVID-19, according to a new study.
Two common antidepressant and antifungal drugs were very effective at inhibiting SARS-CoV-2, the virus that causes COVID-19, according to a new study.
Researchers found that the antifungal itraconazole (Sporanox, other brand names) and the antidepressant fluoxetine (Prozac), in combination with the antiviral drug remdesivir, inhibited the production of SARS-CoV-2 by more than 90%.
Related: Merck’s experimental drug shows quick reduction in SARS-CoV-2
The study was published April 6 in. the British Journal of Pharmacology.
Researchers tested the antiviral potential of itraconazole and fluoxetine on the production of infectious SARS‐CoV‐2 particles — alone and in combination with remdesivir — using a cell culture model in the lab.
Related: FDA authorizes new COVID-19 treatment, more vaccine doses on the way
Importantly, both the itraconazole–remdesivir and fluoxetine–remdesivir combinations displayed synergistic effects, as determined in commonly used reference models for drug interaction, wrote senior author Ursula Rescher, PhD, with the University of Muenster, Germany, and colleagues.
“Itraconazole–remdesivir and fluoxetine–remdesivir combinations are promising starting points for therapeutic options to control SARS‐CoV‐2 infection and severe progression of COVID‐19,” they wrote.
Read more: FDA okays first combo COVID-19 and flu test
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
